Skip to Content
You are currently on the new version of our website. Access the old version .
Current OncologyCurrent Oncology
  • Article
  • Open Access

18 November 2023

11 Pages

Low-Grade Pseudomyxoma Peritonei Behaving as a High-Grade Disease: A Case Series and Literature Review

,
,
and
1
University Surgery Department, Papageorgiou Hospital, Aristotle University of Thessaloniki, 54453 Thessaloniki, Greece
2
Department of Surgical Oncology, Peritoneal Surface Malignancy Program, Euromedica Kyanos Stavros, 54454 Thessaloniki, Greece
3
Department of Anaesthesiology, Euromedica Kyanos Stavros, 54454 Thessaloniki, Greece
*
Author to whom correspondence should be addressed.

Abstract

Patients with low-grade appendiceal mucinous carcinomas (LAMNs) treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have a favorable prognosis. However, a subgroup of patients presents a clinically aggressive course with disease progression despite receiving treatment. The purpose of this study is to report the experience of clinically aggressive LAMN patients treated by the same team, and to present a review of the literature. The cases of four patients with clinically aggressive LAMNs were reviewed. Clinical and histopathological characteristics were re-examined. Recurrences and the time of recurrence, as well as the survival time, were recorded. These patients were four men with clinically aggressive LAMNs treated with CRS plus HIPEC. One of them underwent CC-0 surgery, two underwent CC-1 surgery, and one underwent CC-3 surgery. All patients received systemic chemotherapy after surgery. Recurrence was recorded in three of the patients within 4–23 months after the initial treatment. Two of the patients underwent secondary CRS. Three patients died of disease recurrence within 13–23 months, and one is alive with a disease relapse at 49 months after his initial surgery. LAMNs were identified in both the initial specimens and the specimens obtained during reoperation. The prognosis of LAMN patients treated with CRS plus HIPEC is favorable. A small number of patients present a clinically aggressive course that is unresponsive to any treatment. Molecular and genetic studies are required to identify this group of LAMN patients who have an unfavorable prognosis.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.